Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

Lenalidomide (LEN) maintenance (MT) post autologous stem cell transplantation (ASCT) is standard of care in newly diagnosed multiple myeloma (MM) but has not been compared to other agents in clinical trials. We retrospectively compared bortezomib (BTZ; n = 138) or LEN (n = 183) MT from two subsequen...

詳細記述

保存先:
書誌詳細
出版年:Blood Cancer J
主要な著者: Baertsch, Marc-Andrea, Mai, Elias K., Hielscher, Thomas, Bertsch, Uta, Salwender, Hans J., Munder, Markus, Fuhrmann, Stephan, Dührsen, Ulrich, Brossart, Peter, Neben, Kai, Schlenzka, Jana, Kunz, Christina, Raab, Marc S., Hillengaß, Jens, Jauch, Anna, Seckinger, Anja, Hose, Dirk, Luntz, Steffen, Sonneveld, Pieter, Lokhorst, Henk, Martin, Hans, Goerner, Martin, Hoffmann, Martin, Lindemann, Hans-Walter, Bernhard, Helga, Blau, Igor W., Scheid, Christof, Besemer, Britta, Weisel, Katja C., Hänel, Mathias, Dürig, Jan, Goldschmidt, Hartmut
フォーマット: Artigo
言語:Inglês
出版事項: Nature Publishing Group UK 2021
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7791127/
https://ncbi.nlm.nih.gov/pubmed/33414374
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-020-00390-3
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料